(s)-(+)-3-(benzyloxycarbonyl)-5-oxo-4-oxazolidineacetic acid - CAS 23632-66-8

(s)-(+)-3-(benzyloxycarbonyl)-5-oxo-4-oxazolidineacetic acid is a oxazolidinone derivative for the stereoselective formation of C-C and C-X (X = O, N, Br, F, etc.) bonds.

Product Information

Canonical SMILES
C1N(C(C(=O)O1)CC(=O)O)C(=O)OCC2=CC=CC=C2
InChI
InChI=1S/C13H13NO6/c15-11(16)6-10-12(17)20-8-14(10)13(18)19-7-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H,15,16)/t10-/m0/s1
InChI Key
XGNNOKSIFRVHHA-JTQLQIEISA-N
Purity
95%
MDL
MFCD00799474
Boiling Point
555.6°C at 760mmHg
Melting Point
84-87°C
Density
1.411g/cm3
Optical Activity
+137°( c = 3.5 in methanol)
WGK Germany
3

Safety Information

Signal Word
Warning
Precautionary Statement
P302+P352 - P305+P351+P338
Hazard Statements
H315 - H319 - H335

Reference Reading

1.Solid-Phase Synthesis, Hybridizing Ability, Uptake, and Nuclease Resistant Profiles of Position-Selective Cationic and Hydrophobic Phosphotriester Oligonucleotides.
Monfregola L1, Caruthers MH1. J Org Chem. 2015 Sep 18;80(18):9147-58. doi: 10.1021/acs.joc.5b01512. Epub 2015 Sep 3.
Analogues of oligonucleotides and mononucleotides with hydrophobic and/or cationic phophotriester functionalities often generate an improvement in target affinity and cellular uptake. Here we report the synthesis of phosphotriester oligodeoxyribonucleotides (ODNs) that are stable to the conditions used for their preparation. The method has been demonstrated by introducing phosphoramidite synthons where N-benzyloxycarbonyl (Z) protected amino alcohols replace the cyanoethyl group. After synthesis these ODNs were found to be stable to the condition required to remove base labile protecting groups and the ODNs from the solid support. Moreover the use of 1-(4,4-dimethyl-2, 6-dioxocyclohex-1-ylidene) ethyl (Dde) in place of Z protection on the amino alcohol has allowed us to introduce cationic aminoethyl phosphotriester modifications into ODNs. Melting temperatures of duplexes containing cationic or hydrophobic Z modified ODNs indicate that the backbone-phosphotriester modifications minimally affect duplex stability.
2.TNF-α regulates miRNA targeting mitochondrial complex-I and induces cell death in dopaminergic cells.
Prajapati P1, Sripada L1, Singh K1, Bhatelia K1, Singh R2, Singh R3. Biochim Biophys Acta. 2015 Mar;1852(3):451-61. doi: 10.1016/j.bbadis.2014.11.019. Epub 2014 Dec 4.
Parkinson's disease (PD) is a complex neurological disorder of the elderly population and majorly shows the selective loss of dopaminergic (DAergic) neurons in the substantia nigra pars compacta (SNpc) region of the brain. The mechanisms leading to increased cell death of DAergic neurons are not well understood. Tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine is elevated in blood, CSF and striatum region of the brain in PD patients. The increased level of TNF-α and its role in pathogenesis of PD are not well understood. In the current study, we investigated the role of TNF-α in the regulation of cell death and miRNA mediated mitochondrial functions using, DAergic cell line, SH-SY5Y (model of dopaminergic neuron degeneration akin to PD). The cells treated with low dose of TNF-α for prolonged period induce cell death which was rescued in the presence of zVAD.fmk, a caspase inhibitor and N-acetyl-cysteine (NAC), an antioxidant.
3.Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma.
McCabe KE1, Bacos K1, Lu D2, Delaney JR1, Axelrod J1, Potter MD1, Vamos M3, Wong V1, Cosford ND3, Xiang R4, Stupack DG1. Cell Death Dis. 2014 Oct 30;5:e1496. doi: 10.1038/cddis.2014.448.
Ovarian cancer patients are typically treated with carboplatin and paclitaxel, but suffer a high rate of relapse with recalcitrant disease. This challenge has fostered the development of novel approaches to treatment, including antagonists of the 'inhibitor of apoptosis proteins' (IAPs), also called SMAC mimetics, as apoptosis-inducing agents whose action is opposed by caspase inhibitors. Surprisingly, IAP antagonist plus caspase inhibitor (IZ) treatment selectively induced a tumor necrosis factor-α (TNFα)-dependent death among several apoptosis-resistant cell lines and patient xenografts. The induction of necroptosis was common in ovarian cancer, with expression of catalytically active receptor-interacting protein kinase-3 (RIPK3) necessary for death, and in fact sufficient to compromise survival of RIPK3-negative, necroptosis-resistant ovarian cancer cells. The formation of a necrosome-like complex with a second critical effector, receptor-interacting serine-threonine kinase-1 (RIPK1), was observed.
4.Role of the mitochondrial pathway in serum deprivation-induced apoptosis of rat endplate cells.
Li D1, Zhu B2, Ding L3, Lu W4, Xu G5, Wu J6. Biochem Biophys Res Commun. 2014 Sep 26;452(3):354-60. doi: 10.1016/j.bbrc.2014.08.054. Epub 2014 Aug 27.
The apoptosis of cartilage endplates (CEPs), acting as an initiating factor, plays a vital role in the pathogenesis of intervertebral disc degenerative diseases, the underlying molecular mechanism of the apoptotic process in CEPs is still not clear. The present study aimed to investigate the mechanism of CEP cell apoptosis. We found that low levels of fetal bovine serum (FBS) can induce cell apoptosis. Serum deprivation led to high expression levels of caspase-9, caspase-3, PARP, cytochrome-c and Bax. Flow cytometric analysis showed that inhibition of the intrinsic pathway by a caspase-9 inhibitor (z-LEHD-fmk) significantly suppressed serum deprivation-induced apoptosis. However, a caspase-8 inhibitor (z-IETD-fmk) did not reduce apoptotic cell death. These data suggest that serum deprivation induces apoptosis in rat CEP cells via the activation of the intrinsic apoptotic pathway. The efficacy of a caspase-9 inhibitor in attenuating or preventing apoptosis of serum deprivation-induced disc cell apoptosis suggests that targeting the intrinsic apoptotic pathway may be used as a potential therapy for the treatment of disc degeneration.
The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

USA
  • International:
  • US & Canada (Toll free):
  • Email:
  • Fax:
UK
  • Email:
Copyright © 2024 BOC Sciences. All rights reserved.